Form 8-K - Current report:
SEC Accession No. 0001564590-21-054227
Filing Date
2021-11-04
Accepted
2021-11-04 07:01:48
Documents
14
Period of Report
2021-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K agle-8k_20211104.htm   iXBRL 8-K 42190
2 EX-99.1 agle-ex991_6.htm EX-99.1 303611
3 GRAPHIC gnpfq1wdjvto000001.jpg GRAPHIC 12575
  Complete submission text file 0001564590-21-054227.txt   510744

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA agle-20211104.xsd EX-101.SCH 5673
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20211104_lab.xml EX-101.LAB 20078
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20211104_pre.xml EX-101.PRE 11925
7 EXTRACTED XBRL INSTANCE DOCUMENT agle-8k_20211104_htm.xml XML 3683
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 211377937
SIC: 2834 Pharmaceutical Preparations